Champions Oncology, Inc. (NASDAQ:CSBR)

Champions Oncology, Inc. engages in the development of technology solutions to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, using its Tumorgraft Technology Platform, provides Personalized Oncology Solutions that assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug studies and related personalized oncology services. It also offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies, which uses vivo studies and bioinformatics analysis to predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or in combination with other drugs. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was founded in 1985 and is headquartered in Hackensack, New Jersey.

Last updated June 17, 2013